Dennis Riley - Galera Therapeutics Emeritus Officer
| GRTXDelisted Stock | USD 2.58 0.19 6.86% |
Insider
Dennis Riley is Emeritus Officer of Galera Therapeutics
| Phone | 610 725 1500 |
| Web | https://www.galeratx.com |
Galera Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.5929) % which means that it has lost $0.5929 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.6311) %, meaning that it created substantial loss on money invested by shareholders. Galera Therapeutics' management efficiency ratios could be used to measure how well Galera Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Galera Therapeutics currently holds 152.3 M in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. Galera Therapeutics has a current ratio of 4.92, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Galera Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Galera Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Galera Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Galera to invest in growth at high rates of return. When we think about Galera Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Siew MS | Acumen Pharmaceuticals | N/A | |
| John Lewicki | Mereo BioPharma Group | 72 | |
| Arthur Taveras | X4 Pharmaceuticals | 60 | |
| Jaa Roberson | Day One Biopharmaceuticals | N/A | |
| Matthew CPA | PDS Biotechnology Corp | 55 | |
| Janice Hitchcock | Acumen Pharmaceuticals | N/A | |
| MBBS MD | Mereo BioPharma Group | 54 | |
| James MBA | Amylyx Pharmaceuticals | 57 | |
| Renato Skerlj | X4 Pharmaceuticals | N/A | |
| Andreas Bergthaler | Hookipa Pharma | N/A | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| Marine Popoff | Hookipa Pharma | N/A | |
| Demetrios MD | Inozyme Pharma | N/A | |
| Gina Mazzariello | Amylyx Pharmaceuticals | 53 | |
| Liean MS | Acumen Pharmaceuticals | N/A | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| Russell MS | Acumen Pharmaceuticals | 66 | |
| Jackie Parkin | Mereo BioPharma Group | 66 | |
| MS MBA | Inozyme Pharma | 47 | |
| Prof MD | Hookipa Pharma | 80 | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
Management Performance
| Return On Equity | -10.63 | ||||
| Return On Asset | -0.59 |
Galera Therapeutics Leadership Team
Elected by the shareholders, the Galera Therapeutics' board of directors comprises two types of representatives: Galera Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Galera. The board's role is to monitor Galera Therapeutics' management team and ensure that shareholders' interests are well served. Galera Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Galera Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mel MD, President CEO | ||
| Dr MBA, CoFounder COO | ||
| Jennifer Esq, Chief Secretary | ||
| Andie Collier, Chief Officer | ||
| FACS FACS, Chief Officer | ||
| Christopher Degnan, Chief Officer | ||
| PharmD MBA, Chief Officer | ||
| Jon MD, Ex Officer | ||
| Dennis Riley, Emeritus Officer | ||
| Judy Schnyder, Senior Management |
Galera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Galera Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.63 | ||||
| Return On Asset | -0.59 | ||||
| Current Valuation | 146.68 M | ||||
| Shares Outstanding | 54.39 M | ||||
| Shares Owned By Insiders | 36.15 % | ||||
| Shares Owned By Institutions | 18.95 % | ||||
| Number Of Shares Shorted | 2.12 M | ||||
| Price To Earning | (0.78) X | ||||
| Price To Book | 29.39 X | ||||
| EBITDA | (46.69 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Galera Pink Sheet
If you are still planning to invest in Galera Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Galera Therapeutics' history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |